Total Payments
$366,491
2024 Payments
$138,285
Companies
34
Transactions
493
Medicare Patients
11,030
Medicare Billing
$818,286
Payment Breakdown by Category
Research$341,836 (93.3%)
Food & Beverage$10,496 (2.9%)
Other$6,260 (1.7%)
Consulting$3,975 (1.1%)
Travel$3,733 (1.0%)
Education$190.48 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $341,836 | 62 | 93.3% |
| Food and Beverage | $10,496 | 407 | 2.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 2 | 1.6% |
| Consulting Fee | $3,975 | 2 | 1.1% |
| Travel and Lodging | $3,733 | 15 | 1.0% |
| Honoraria | $260.08 | 2 | 0.1% |
| Education | $190.48 | 3 | 0.1% |
Payments by Type
Research
$341,836
62 transactions
General
$24,655
431 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Nielsen BioSciences, Inc. | $195,988 | 3 | $0 (2024) |
| Bausch Health US, LLC | $120,320 | 17 | $0 (2021) |
| Endo Pharmaceuticals Inc. | $10,269 | 6 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $9,908 | 5 | $0 (2017) |
| Galderma Laboratories, L.P. | $8,358 | 19 | $0 (2024) |
| ABBVIE INC. | $5,146 | 89 | $0 (2024) |
| SANOFI US SERVICES INC. | $3,767 | 23 | $0 (2024) |
| PFIZER INC. | $2,481 | 17 | $0 (2024) |
| LEO Pharma Inc. | $1,260 | 75 | $0 (2024) |
| UCB SA | $1,165 | 13 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $138,285 | 137 | Nielsen BioSciences, Inc. ($124,660) |
| 2023 | $4,711 | 89 | SANOFI US SERVICES INC. ($1,969) |
| 2022 | $908.76 | 39 | ABBVIE INC. ($379.53) |
| 2021 | $2,970 | 50 | AbbVie Inc. ($2,199) |
| 2020 | $1,699 | 40 | UCB GmBH ($995.54) |
| 2019 | $1,848 | 42 | Bausch Health US, LLC ($900.00) |
| 2018 | $121,825 | 46 | Bausch Health US, LLC ($119,375) |
| 2017 | $94,246 | 50 | Nielsen BioSciences, Inc. ($70,682) |
All Payment Transactions
493 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $21.24 | General |
| 12/20/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Immunology | ||||||
| 12/20/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Immunology | ||||||
| 12/13/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Immunology | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.59 | General |
| Category: Immunology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.86 | General |
| Category: Immunology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $33.42 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $5.30 | General |
| Category: Immunology | ||||||
| 12/02/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: DERMATOLOGY | ||||||
| 11/30/2024 | Nielsen BioSciences, Inc. | Candin (Biological) | — | Cash or cash equivalent | $124,660.46 | Research |
| Study: CFW-3A • Category: Immunotherapy | ||||||
| 11/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $41.31 | General |
| Category: Immunology | ||||||
| 11/22/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $4.77 | General |
| 11/20/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Immunology | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $19.66 | General |
| Category: Dermatology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $41.57 | General |
| Category: Immunology | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $7.49 | General |
| Category: Immunology | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $23.52 | General |
| Category: Immunology | ||||||
| 11/04/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $25.23 | General |
| Category: DERMATOLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CFW-3A | Nielsen BioSciences, Inc. | $124,660 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $120,275 | 16 |
| CFW-2D | Nielsen BioSciences, Inc. | $71,327 | 2 |
| Reliability and Validity of the Clinician-reported Photonumeric Cellulite Severity Scale CR-PCSS in Live Subjects | Endo Pharmaceuticals Inc. | $10,269 | 6 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $5,154 | 2 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $4,700 | 2 |
| Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $3,767 | 23 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | ABBVIE INC. | $1,600 | 9 |
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $83.79 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 3,558 | 7,059 | $1.2M | $272,652 |
| 2022 | 15 | 2,533 | 5,003 | $820,536 | $193,842 |
| 2021 | 15 | 2,577 | 5,039 | $817,527 | $202,208 |
| 2020 | 14 | 2,362 | 4,548 | $679,860 | $149,585 |
Total Patients
11,030
Total Services
21,649
Medicare Billing
$818,286
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 984 | 1,282 | $320,500 | $87,523 | 27.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 511 | 613 | $190,260 | $45,816 | 24.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 684 | 952 | $190,400 | $40,589 | 21.3% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 144 | 199 | $84,575 | $17,855 | 21.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 536 | 3,212 | $122,056 | $17,380 | 14.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 84 | 96 | $48,000 | $13,827 | 28.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 131 | 131 | $45,900 | $10,782 | 23.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 56 | 65 | $30,875 | $9,201 | 29.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 141 | 190 | $28,500 | $8,119 | 28.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 112 | 120 | $24,750 | $5,325 | 21.5% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 36 | 40 | $16,000 | $3,772 | 23.6% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 24 | 25 | $12,500 | $3,669 | 29.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 35 | 39 | $12,300 | $3,264 | 26.5% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 25 | 26 | $11,900 | $2,819 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $4,350 | $1,182 | 27.2% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $5,700 | $1,026 | 18.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 12 | 14 | $4,550 | $485.38 | 10.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 24 | $240.00 | $18.47 | 7.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 716 | 980 | $245,000 | $66,238 | 27.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 442 | 528 | $158,940 | $38,218 | 24.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 465 | 679 | $135,800 | $28,300 | 20.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 367 | 2,192 | $83,296 | $12,151 | 14.6% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 59 | 72 | $36,000 | $9,636 | 26.8% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 73 | 90 | $38,250 | $8,702 | 22.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 129 | 138 | $28,200 | $5,613 | 19.9% |
About Dr. Mark Amster, MD
Dr. Mark Amster, MD is a Dermatology healthcare provider based in Brighton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518947068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Amster, MD has received a total of $366,491 in payments from pharmaceutical and medical device companies, with $138,285 received in 2024. These payments were reported across 493 transactions from 34 companies. The most common payment nature is "" ($341,836).
As a Medicare-enrolled provider, Amster has provided services to 11,030 Medicare beneficiaries, totaling 21,649 services with total Medicare billing of $818,286. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Brighton, MA
- Active Since 01/19/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1518947068
Products in Payments
- Candin (Biological) $195,988
- XIAFLEX (Biological) $10,269
- EUCRISA (Drug) $2,481
- RINVOQ (Biological) $2,314
- HUMIRA (Biological) $2,089
- COSENTYX (Biological) $913.82
- ENSTILAR (Drug) $669.68
- TREMFYA (Drug) $669.55
- OPZELURA (Drug) $667.26
- Bimzelx (Biological) $499.65
- Sotyktu (Drug) $445.29
- SKYRIZI (Biological) $440.27
- DUPIXENT (Biological) $384.98
- TALTZ (Drug) $346.80
- PICATO (Drug) $265.40
- ADBRY (Biological) $256.18
- Otezla (Drug) $177.42
- Cimzia (Drug) $170.09
- DORYX (Drug) $157.44
- REMICADE (Biological) $156.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Brighton
Dr. Howard Lipkin, D.o, D.O
Dermatology — Payments: $59,877
Dermatology $59,877
Mrs. Caitlin Porubsky, D.o, D.O
Dermatology — Payments: $14,577
Dermatology $14,577
Mrs. Jennifer Gangnier, Pa-C, PA-C
Dermatology — Payments: $4,155
Dermatology $4,155
Elizabeth Messenger, Md, MD
Dermatology — Payments: $1,970
Dermatology $1,970
Robert Brown, Md, MD
Dermatology — Payments: $1,763
Dermatology $1,763
Dr. Claudette Mcgoey, M.d, M.D
Dermatology
Dermatology